Credevo, Singapore (2026)

11/09/2026

Tables, Listings, and Figures (TLFs) are what the regulator reads.

Everything before them is preparation: the Statistical Analysis Plan (SAP), the statistical analysis, the programming.

When a statistical analysis is complete, the output is not a narrative. It is a set of structured tables showing numerical results by visit, by analysis set, by treatment group. A set of listings showing patient-level data in defined formats. A set of figures summarising study outcomes.

These are the TLFs. They are produced from the locked dataset, according to the SAP that was written and approved before the first patient was enrolled. They are what the Clinical Study Report (CSR) references. They are what a regulatory reviewer works from when assessing whether the study was conducted and analysed as described.

For submissions using CDISC-compliant datasets, TLF outputs are built from Analysis Data Model (ADaM) datasets. The format, conventions, naming, and variable labels follow the applicable regulatory submission standards.

For sponsors where biostatistics is not part of a full-service Contract Research Organisation (CRO) engagement, getting to a regulatory-ready TLF set from raw data requires statistical programming expertise and knowledge of what each authority's submission standards require.

Credevo provides standalone biostatistics: SAP writing and lock, sample size estimation and power calculations, statistical analysis and reporting, and TLFs prepared to International Council for Harmonisation (ICH) E3 standards. Available as a standalone engagement for sponsors who need the statistical deliverables without a full CRO model.

We've covered the scope of clinical biostatistical support and what each component involves.

https://credevo.com/articles/2022/01/05/clinical-biostatistics-its-importance-in-clinical-trials/

If you're at the analysis stage and need a clearer picture of what the statistical deliverable package looks like for your submission, we'd be glad to walk through it: https://credevo.com/contact

10/09/2026

The per-patient cost is the number sponsors plan from first.

It shows up in proposals, in budget templates, and in early feasibility conversations. For two countries at different cost levels, the per-patient comparison is the natural starting point.

But a Phase II study running across two markets has more variables than per-patient costs.

Startup duration varies by study type and market. The regulatory review cycle, IRB process, and site contracting timeline in each country follow their own structure. A well-prepared submission can move through a market in a predictable window. An under-prepared one triggers deficiency letters that extend startup by weeks or months. That extension has a cost: in team time, in investigational product shelf life, in sponsor-side overhead, and in the milestone calendar the sponsor is working against.

Recruitment variability adds another layer. The available patient pool at selected sites is confirmed through site-level feasibility. When recruitment runs slower than projected, the study timeline extends. When it runs faster, the study can close early. Projecting this accurately requires knowing the actual sites, the actual investigators, and the competing study landscape, not benchmarks from a historical database.

Budget benchmarking done well compares total cost of ex*****on across the full study lifecycle: startup, ex*****on, and close-out, across the markets in scope, with realistic assumptions about query cycles and recruitment variability.

Credevo provides budget and timeline benchmarking as part of the Extended Clinical Development model and as a standalone advisory service: realistic assessment of sponsor plans against target market realities.

We've written about budget challenges in clinical trials and what cost management in practice actually involves.

https://credevo.com/articles/2025/12/25/navigating-budget-challenges-in-clinical-trials-practical-strategies-for-cost-management/

If you're comparing markets and want a realistic view of what total study cost looks like across your options, we'd be glad to help: https://credevo.com/contact

09/09/2026

A Phase III study in India was approaching a regulatory inspection at two of its active sites.

The sites were experienced. Monitoring had been ongoing throughout the study. No compliance concerns had been flagged.

But the study was running under International Council for Harmonisation (ICH) E6(R3), the current Good Clinical Practice (GCP) standard, and several site staff had trained under the previous version. The standard had been updated. The training had not been refreshed to match what inspectors were now looking at.

A GCP training workshop was delivered at both sites in the weeks before the inspection. It covered ICH E6(R3) practical implementation, documentation and audit trail requirements under the current standard, inspection readiness for GCP compliance under the CDSCO framework, and a walkthrough of each site to identify documentation gaps before the inspector arrived.

Three issues were found during that walkthrough.

Several informed consent forms had been filed without the participant having written the date in their own hand, as required under E6(R3).

Audit trail documentation for one Electronic Data Capture (EDC) system was accessible but not organised in the format an inspection team would request.

One investigator file was missing the most recent version of the Investigator's Brochure (IB).

Each was correctable before the inspection. None would have been visible in a standard monitoring visit.

The inspection was completed without major findings.

Credevo provides GCP and inspection readiness training as a standalone service, customised for sites, investigators, and site staff, and available either as study-specific training integrated into startup or as dedicated preparation ahead of a scheduled inspection.

We've written about what a Quality Management System (QMS) framework looks like in clinical trial ex*****on and the GCP compliance principles that support inspection readiness.

https://credevo.com/articles/2025/03/15/quality-by-design-in-clinical-trials-building-maintaining-a-qms-framework/

If you have a study approaching a regulatory inspection and want to understand what readiness preparation covers, we would be glad to talk through it with you: https://credevo.com/contact

08/09/2026

Every APAC regulatory authority publishes its requirements.

What gets published and what actually happens in review are not the same document.

A sponsor approaching their first submission to CDSCO (India's Central Drugs Standard Control Organisation) reads the published guidance. The submission format is documented. The timelines are listed. The requirements for a Phase II application are described.

Then the actual submission goes in.

Deficiency letters come back. The queries reference areas of the dossier that were not flagged during pre-submission review. The response window opens. How the re-review cycle moves from that point onward is not described in published documentation. It depends on the nature of the queries and the completeness of the original submission.

This is not unique to India. Every APAC authority Credevo works with has a published framework and a practical reality. The National Pharmaceutical Regulatory Agency (NPRA) in Malaysia has its own query patterns. The Sri Lanka National Medicines Regulatory Authority (NMRA) has a review process less externally documented than larger markets. The Drug Administration of Vietnam (DAV) has its own format expectations. Understanding how submissions move through each authority requires having been through submissions there.

A Contract Research Organisation (CRO) embedded in these markets knows which query types are most common for specific study categories, what preparation reduces deficiency rates, and how to manage the response cycle efficiently.

Credevo manages regulatory submissions across all 13 markets where we operate. For each country in scope, the answer to what the regulatory process actually looks like comes from what recent submissions in that market have looked like in practice.

We've written about what clinical operations in Asia-Pacific actually involves and the regulatory realities sponsors encounter.

https://credevo.com/articles/2025/08/15/mastering-clinical-operations-in-asia-pacific-overcoming-challenges-with-smart-solutions/

If the regulatory pathway for a specific market is part of what you're planning, we would be glad to walk through it with you: https://credevo.com/contact

07/09/2026

An underpowered study is one where the sample size is insufficient to detect a real effect at the target power level, meaning it cannot answer the primary question it was designed to answer, regardless of how the data trends.

Sample size and statistical power are calculated before a study starts, based on four inputs: the primary endpoint, the expected effect size, the acceptable alpha level, and the required statistical power. Those inputs need to be specified carefully. If the expected effect size is too optimistic, the study will not detect a real effect at the sample size calculated. If the power target is too low, the probability of a false negative rises.

For sponsors running their first regulated study, or sponsors who have received a proposal without a clear sample size justification, this is the moment to ask: what was the expected effect size based on? What is the power of this study? What happens to the sample size if the effect is 10% smaller than assumed?

These are not optional questions. An underpowered study that misses its primary endpoint does not prove that the intervention did not work. It proves the study was not designed to detect the effect if it existed. For sponsors, that distinction is expensive.

Credevo provides standalone biostatistics: sample size estimation and power calculations, Statistical Analysis Plan (SAP) writing and lock, statistical analysis and reporting, and Tables, Listings, and Figures (TLFs) prepared to International Council for Harmonisation (ICH) E3 standards. These services are available as standalone engagements, for sponsors who need statistical expertise without full Contract Research Organisation (CRO) engagement.

We've written about what to look for when choosing biostatistical support and how sample size justification fits into study planning.

https://credevo.com/articles/2022/08/25/important-tips-while-choosing-a-biostatistician-for-your-clinical-trials/

If you are at the study planning stage and want to check whether your power assumptions hold up, we would be glad to work through it with you: https://credevo.com/contact

04/09/2026

Published regulatory timelines are the best-case scenario.

Every regulatory authority in APAC has documented requirements: submission dossier contents, review timelines, deficiency response periods. The documentation is publicly available. Contract Research Organisations (CROs) and sponsors reference it regularly to set expectations at the start of a study.

What it does not describe is what submissions actually look like in practice.

The Thailand Food and Drug Administration review timeline for a Phase II study depends partly on study design and drug category, and partly on the current reviewer workload and the completeness of the dossier submitted. Deficiency letters are common. The re-review cycle that follows a deficiency response varies by the nature of the question and how the response is prepared. Sponsors who have been through this before know that the published timeline and the actual timeline are not the same number.

The National Pharmaceutical Regulatory Agency (NPRA) in Malaysia has its own submission format, its own query patterns, and its own pace of review. The Sri Lanka National Medicines Regulatory Authority (NMRA) has a review process that is less documented in external materials than markets like Singapore or India. Understanding how submissions move through the NMRA requires having been through submissions there.

This is what knowing a market means: not access to the published framework, but a record of how submissions move, where the common friction points are, and what preparation reduces query rates.

When sponsors ask Credevo about the regulatory timeline for a specific study type in a specific market, the answer comes from what recent submissions in that market have looked like in practice.

We have written about what clinical operations in Asia-Pacific actually involves and the challenges sponsors encounter running studies across these markets.

https://credevo.com/articles/2025/08/15/mastering-clinical-operations-in-asia-pacific-overcoming-challenges-with-smart-solutions/

If you want a plain answer about what the regulatory process looks like for your study type in a specific market, we are here: https://credevo.com/contact

03/09/2026

Country plans built on published patient population data and regional regulatory timelines carry assumptions that site-level feasibility tests directly, and the tests do not always confirm the plan.

In a Phase II oncology program across three markets, feasibility surfaced two material changes.

The first: one of the three countries had a patient population that looked right on paper. When site-level feasibility ran with investigators who knew the indication, it became clear that investigators with experience in the specific tumour subtype were concentrated at sites already running a competing study in the same area. Activation was possible, but the competing study created a narrow window. If the sponsor's study took longer than planned to reach site initiation visits, the available investigator capacity would close.

The second: a country not in the original plan had investigators who had been engaged early and expressed direct interest when the study was described to them. Their sites had infrastructure for the indication, relevant patient access, and no competing study load. The feasibility numbers there were better than the marginal market in the original plan.

The sponsor revised the plan before startup. The third country was replaced. The substituted country was added with a confirmed site list. The study activated within the planned window.

Feasibility does not confirm the plan. It tests whether the plan holds up against what is actually available in the markets you are planning to use.

We have written about what rethinking feasibility in APAC actually looks like and what early investigator engagement surfaces that desk reviews miss.

https://credevo.com/articles/2025/07/25/beyond-the-feasibility-questionnaire-rethinking-feasibility-assessments-in-asia-pacific-trials/

If you are at the feasibility stage for a study and want to understand what a real feasibility process surfaces, we would be glad to talk through it with you: https://credevo.com/contact

02/09/2026

A nutraceutical brand wants a study they can publish. A dental hygiene company wants a study that regulators in their target markets will accept. A probiotic company wants to know whether the claim they are planning to make is supportable before committing to a full study.

In each case, they know what they want at the end. They do not always know what kind of study gets them there.

The study type, country, and scale all follow from the objective. For a nutraceutical brand making a specific claim, the first question is whether the evidence base for that claim is strong enough to support the endpoint and sample the study would require. For a dental hygiene company, it is which journals have published studies with a comparable design, what sample sizes those studies used, and whether a single-site study is appropriate given what is being measured and the expected effect size. For the probiotic company, a pilot study may be the right starting point: assess whether the effect is detectable at all and whether the variability in the target population supports a powered full study later.

Getting the study type right requires starting with the objective and working backwards. A Contract Research Organisation (CRO) that produces a standard proposal without understanding the specific objective is applying the wrong framework.

Credevo works across pharmaceuticals, nutraceuticals, supplements, consumer health, and hygiene products. The design is always calibrated to what the sponsor needs at the end: what the relevant journals, regulatory bodies, or markets require to accept the evidence the study will produce.

We have written about how to validate nutraceutical claims through clinical trials and what the study design choices involved in doing that actually look like.

https://credevo.com/articles/2024/09/05/validating-nutraceutical-claims-with-clinical-trials-a-comprehensive-guide/

If you are trying to work out what kind of study fits your objective, we would be glad to think through it with you: https://credevo.com/contact

01/09/2026

Contract Research Organisation (CRO) content about APAC follows a recognisable pattern.

A map with dots. A list of reasons why the region is attractive for clinical research. Summaries of regulatory pathways that restate what is already in the published guidance.

None of it describes what operating in APAC actually involves.

It does not tell a sponsor what a query from Thailand's Food and Drug Administration looks like in practice: what documents are requested, how the re-review process runs, and what timelines have looked like for similar study types in recent submissions. It does not say what an ethics committee in Sri Lanka consistently expects beyond the published requirements. It does not say which investigators in a specific city have access to the patient subtype a study needs and which sites are currently at capacity with a competing program.

That information comes from working in those markets, with those regulatory bodies and investigators, over time, it is built through operating experience, not derived from market analysis.

Credevo operates across 13 countries: Singapore, Thailand, Malaysia, India, Sri Lanka, Vietnam, Philippines, Australia, New Zealand, Japan, South Korea, Taiwan, and the United States. In the core markets, teams are embedded locally. They know the regulatory staff, the investigator community, the sites, and how processes actually move.

When a sponsor asks what the regulatory timeline looks like for a specific study type in Malaysia, the answer comes from what recent in-market submissions have actually looked like, grounded in operating experience rather than the published framework.

That is what local presence means in practice.

We've written about what clinical operations in Asia-Pacific actually looks like and the challenges that arise in practice for sponsors running studies across these markets.

https://credevo.com/articles/2025/08/15/mastering-clinical-operations-in-asia-pacific-overcoming-challenges-with-smart-solutions/

If you're evaluating APAC for a study and want a plain answer about what the process actually involves in a specific market, we're here: https://credevo.com/contact

31/08/2026

Database lock in a multi-site APAC study depends on the query management and discrepancy resolution cycle that runs after CRF data entry, a process less visible to sponsors than data entry itself, and the one that determines when biostatistics can begin.

When Case Report Form (CRF) data is entered, it is checked against validation rules, logical checks, and cross-field consistency requirements. An entry outside the expected range, a date that precedes an event it should follow, or a field inconsistent with another field in the same record will trigger a query. Each query goes to the site. The site reviews and responds. The data manager reviews the response. Where the response resolves the discrepancy, the query is closed and the data corrected. Where it does not, the query stays open until it is.

For a multi-site study across APAC markets, the query volume is not small. Sites respond at different speeds. Some responses require follow-up clarification. Some queries involve clinical judgement calls that need the investigator, not just the site coordinator.

The time between last patient, last visit and database lock is determined by how long this process takes. For sponsors running their first multi-country APAC study, this phase is the one that compresses timelines they assumed were already accounted for.

Credevo provides standalone data management: CRF data entry, query generation and resolution, discrepancy management, data cleaning, and database lock. Coverage extends to CDISC-compliant dataset preparation for regulatory submissions.

We've written about clinical data management and biostatistics and how the two connect in clinical trial ex*****on.

https://credevo.com/articles/2021/06/15/clinical-data-management-biostatistics-for-your-clinical-trials/

If you're planning a study and want to understand what data management looks like from entry through lock, we'd be glad to walk through it with you: https://credevo.com/contact

Credevo

11/09/2026

10/09/2026

09/09/2026

08/09/2026

07/09/2026

04/09/2026

03/09/2026

02/09/2026

01/09/2026

31/08/2026

Address

Website

Alerts

Shortcuts

Share

Category

Listing takedown request